Aromazin is an aromatase inhibitor, an anticancer drug.
Release form and composition
The drug is available in the form of sugar-coated tablets, each of which contains:
- 25 mg of exemestane;
- Auxiliary components such as hypromellose, mannitates, crospovidone, microcrystalline cellulose, magnesium stearate, hydrated colloidal silicon dioxide, polysorbate 80, and sodium carboxymethyl starch.
The sugar envelope contains methyl p-hydroxybenzoate, simethicone emulsion, titanium dioxide, polyvinyl alcohol, hypromellose, magnesium carbonate, sucrose, macrogol 6000.
Aromasin tablets are sold in 15 pcs. in blister packs packed in cartons.
Indications for use
As indicated in the instructions for Aromasin, this drug is intended:
- For the treatment of advanced breast cancer in women in induced or natural postmenopause, if the disease progresses as a result of anti-estrogen therapy, as well as with the progression of the disease, despite repeated use of different types of hormonal therapy;
- As an adjuvant (adjuvant) treatment of early breast cancer in postmenopausal women with unknown receptor status or with estrogen-positive receptors in order to reduce the risk of recurrence after the end of the previous 2-3-year adjuvant therapy with tamoxifen, as well as contralateral breast cancer glands.
According to the annotation to the drug, the use of Aromazin is contraindicated:
- During lactation;
- During pregnancy;
- Women with premenopausal endocrine status;
- In the presence of hypersensitivity to exemestane or any auxiliary component of the drug.
Aromasin should be used with caution in patients with impaired liver / kidney function.
Dosing and Administration
Aromasin tablets, according to the instructions, are taken orally at a dose of 25 mg once a day, i.e. 1 tablet, preferably after a meal.
The duration of treatment is determined by the doctor depending on the clinical picture. Patients with early breast cancer are advised to continue therapy until the total duration of the adjuvant treatment is 5 years.
Treatment of advanced breast cancer is long lasting. It should be noted that if the patient shows signs of progression of the disease, or there is contralateral cancer, the use of Aromasin should be stopped.
Aromasin may have side effects, however, according to reviews, when taken in a daily dose of 25 mg, unwanted reactions from the body are insignificant or moderately expressed.
Thus, during clinical studies the following side effects of the drug were identified:
- More than 10% of women: nausea, headache, insomnia, flushing, sweating, fatigue;
- More than 1%, but less often than 10%: anorexia, diarrhea, leg edema, constipation, dyspepsia, abdominal pain, vomiting, depression, carpal tunnel syndrome, dizziness, alopecia, skin rash, musculoskeletal and joint pain, peripheral edema, pain of unspecified location.
Approximately 20% of patients (especially those who had the original lymphopenia - a decrease in the content of lymphocytes in the blood) periodically showed a decrease in lymphocytes. However, a concomitant increase in the incidence of viral infections was not observed.
In individual cases, it is possible to increase the activity of liver enzymes and alkaline phosphatase, mainly in women who have liver damage and metastases in bone and liver. It is also important to clarify: whether these changes are directly related to the use of Aromasin, has not been reliably established.
Cases of overdose of this drug have not been registered in medical practice, and therefore a single dose has not been established that could provoke the development of conditions dangerous for the patient’s life. It is worth noting that with a single dose of 800 mg of exemestane in healthy women and a daily intake of 600 mg in postmenopausal women with advanced breast cancer, no negative reactions from the body were observed, while the recommended daily dose of Aromasin is only 25 mg. However, independently increasing the dosage is strictly prohibited.
Aromasin is not intended for use in women with premenopausal endocrine status. In cases where it is clinically justified, the postmenopausal status needs to be confirmed using studies determining the level of estradiol, luteinizing and follicle-stimulating hormones.
Aromasin is not pharmaceutically compatible with drugs that contain estrogens, since these hormones completely level (negate) its pharmacological action.
One of the possible side effects of this medication is dizziness, drowsiness and asthenia. This should be taken into account for women who drive a car or are engaged in potentially hazardous activities that require quick reactions, visual acuity and / or increased concentration of attention.
Analogues of Aromasin are the following drugs:
- According to the active substance: Aromeston and Eksemestanan-Teva;
- According to the purpose and mechanism of action: Axastrol, Anabrez, Anastera, Anastrozol, Anastrex, Arimidex, Vero-Anastrozol, Lestrodex, Letroz, Letrozol, Letrosan, Letroter, Mammozol, Nexazol, Oreta, Selana, Femara, Egistrazol, Exter, Exter, Exter, Exter, Exeter, Exeter, Exeter, Exeterol Etruzil.
Terms and conditions of storage
Aromasin is a drug belonging to List B and dispensed from pharmacies by prescription. It can be stored for 3 years if the conditions recommended by the manufacturer are observed - a dry place protected from sunlight where the temperature does not exceed 30 ºС.